A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 206 participants.
Also called NCT05963022
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 206 participants
- Sponsor
- Registry
-
NCT05963022
-
- Other papers using this trial's data
- Tirzepatide monotherapy in Chinese patients with early type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial (SURPASS-CN-MONO)
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT05963022. Randomized; double masking; primary purpose treatment. Start 2023-08-21 (actual); primary completion 2024-10-09 (actual). Results posted on 2025-10-21.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO)
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Tirzepatide
- Intervention (Drug)
- Placebo
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct05963022- Content hash
115c2a6830fa34b558b4727eeba3b6c89ce622a327c03e2127d837e3b4ca53b2